Outcomes and complications of pelvic lymph node dissection during robotic-assisted radical prostatectomy
被引:66
作者:
Liss, Michael A.
论文数: 0引用数: 0
h-index: 0
机构:
UC San Diego Hlth Syst, Dept Surg, Div Urol, San Diego, CA 92103 USAUC San Diego Hlth Syst, Dept Surg, Div Urol, San Diego, CA 92103 USA
Liss, Michael A.
[1
]
Palazzi, Kerrin
论文数: 0引用数: 0
h-index: 0
机构:
UC San Diego Hlth Syst, Dept Surg, Div Urol, San Diego, CA 92103 USAUC San Diego Hlth Syst, Dept Surg, Div Urol, San Diego, CA 92103 USA
Palazzi, Kerrin
[1
]
Stroup, Sean P.
论文数: 0引用数: 0
h-index: 0
机构:
USN, San Diego Med Ctr, San Diego, CA 92152 USAUC San Diego Hlth Syst, Dept Surg, Div Urol, San Diego, CA 92103 USA
Stroup, Sean P.
[2
]
Jabaji, Ramzi
论文数: 0引用数: 0
h-index: 0
机构:
UC San Diego Hlth Syst, Dept Surg, Div Urol, San Diego, CA 92103 USAUC San Diego Hlth Syst, Dept Surg, Div Urol, San Diego, CA 92103 USA
Jabaji, Ramzi
[1
]
Raheem, Omer A.
论文数: 0引用数: 0
h-index: 0
机构:
UC San Diego Hlth Syst, Dept Surg, Div Urol, San Diego, CA 92103 USAUC San Diego Hlth Syst, Dept Surg, Div Urol, San Diego, CA 92103 USA
Raheem, Omer A.
[1
]
Kane, Christopher J.
论文数: 0引用数: 0
h-index: 0
机构:
UC San Diego Hlth Syst, Dept Surg, Div Urol, San Diego, CA 92103 USA
Vet Affairs San Diego Healthcare Syst, La Jolla, CA USAUC San Diego Hlth Syst, Dept Surg, Div Urol, San Diego, CA 92103 USA
Kane, Christopher J.
[1
,3
]
机构:
[1] UC San Diego Hlth Syst, Dept Surg, Div Urol, San Diego, CA 92103 USA
[2] USN, San Diego Med Ctr, San Diego, CA 92152 USA
[3] Vet Affairs San Diego Healthcare Syst, La Jolla, CA USA
Describe the outcomes and complications of patients who underwent standard pelvic lymphadenectomy (SPLND) and extended PLND (EPLND), or who did not undergo PLND (non-PLND) at the time of robotic-assisted laparoscopic radical prostatectomy (RALP). Retrospective analysis of prospectively collected longitudinal data of 492 RALPs performed by a single surgeon (Kane) over a 5-year period. Patients are subdivided into three treatment groups: 54 EPLND; 231 SPLND; and 207 non-PLND. Indications for EPLND include Gleason score a parts per thousand yen8, PSA a parts per thousand yen10 ng/mL, and higher D'Amico risk group. Patient demographics, perioperative complications, and short-term oncologic outcomes are compared. Patients who underwent EPLND had higher-risk prostate cancer as evidenced by higher mean PSA (8.5 ng/mL), biopsy Gleason sum (a parts per thousand yen8) (57.7 %), and D'Amico risk group (75.9 %), compared to SPLND and/or non-PLND groups (p a parts per thousand currency sign 0.001). The EPLND total lymph node yield was similar compared to SPLND (20 vs. 18; p = 0.070). When the EPLND (n = 41) and SPLND (n = 57) were examined among only high-risk patients, the lymph node (IQR) yields [20 (14-29) vs. 17 (12-23)] and the proportion of positive nodes [29.3 % (12/41) vs. 12.3 % (7/57)] differed significantly (p = 0.048 and p = 0.042, respectively). Complication rates for all groups were similar and lymphocele formation was 5 %; 2.5 % were clinically significant. Robotic PLND can be performed with nodal yield comparable to open or laparoscopic PLND. Robotic EPLND improves nodal yield and the proportion of high-risk patients with nodal metastases recognized. Robotic PLND is associated with an approximately 5 % lymphocele rate. There is no difference in complications between EPLND and SPLND.